Literature DB >> 6510457

Antipyrine clearance in patients with Gilbert's syndrome.

T Ishizaki, K Chiba, T Sasaki.   

Abstract

The pharmacokinetic parameters of antipyrine (AP) were examined in 45 normal healthy subjects (18 heavy smokers, 5 mild smokers, and 22 nonsmokers) and in 12 patients with Gilbert's syndrome (GS), amongst whom 2 mild and 1 heavy smokers were included. Heavy smokers were defined as persons smoking more than 20 cigarettes/day and mild smokers as those smoking less than 10 cigarettes/day. Significant differences (unpaired Student's t-test) in the elimination t1/2 of AP among the study groups and in its total plasma clearance (CL) were observed without any change in the apparent volume of distribution. The individual CL values varied within the same study groups, but the mean +/- SD (0.026 +/- 0.004 l/h/kg) in the GS patients did not significantly differ from that in normal nonsmokers (0.025 +/- 0.006 l/h/kg) or in normal mild smokers (0.028 +/- 0.001 l/h/kg). When the 3 patients with GS who smoked were excluded, the mean CL of the group (0.025 l/h/kg) was again comparable to that of the normal nonsmokers and mild smokers. The mean (+/- SD) CL in normal heavy smokers (0.040 +/- 0.012 l/h/kg) was significantly greater than in normal mild smokers (p less than 0.05), in normal nonsmokers (p less than 0.001) and in patients with GS (p less than 0.001). The results suggest that drug oxidation capacity estimated from the total plasma CL of AP appears unimpaired in GS.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6510457     DOI: 10.1007/bf00542163

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  31 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  PLASMA BILIRUBIN DETERMINATION IN THE NEWBORN INFANT. A METHODOLOGICAL STUDY WITH SPECIAL REFERENCE TO THE INFLUENCE OF HEMOLYSIS.

Authors:  M MICHAUELSSON; B NOSSLIN; S SJOELIN
Journal:  Pediatrics       Date:  1965-06       Impact factor: 7.124

3.  Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination.

Authors:  G W Hepner; E S Vesell; A Lipton; H A Harvey; G R Wilkinson; S Schenker
Journal:  J Lab Clin Med       Date:  1977-09

4.  The influence of cigarette smoking and sex on theophylline disposition.

Authors:  J R Powell; J F Thiercelin; S Vozeh; L Sansom; S Riegelman
Journal:  Am Rev Respir Dis       Date:  1977-07

5.  Environmental effects on antipyrine half-life in man.

Authors:  H S Fraser; J C Mucklow; C J Bulpitt; C Khan; G Mould; C T Dollery
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

6.  Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study.

Authors:  Y Horai; T Ishizaki; T Sasaki; K Chiba; T Suganuma; H Echizen; A Ohnishi
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Influence of sex and oral contraceptive steroids on antipyrine metabolite formation.

Authors:  M W Teunissen; A K Srivastava; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1982-08       Impact factor: 6.875

8.  Impairment of hepatic drug metabolism in alcoholics.

Authors:  A W Harman; D B Frewin; B G Priestly; C B Alexander
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

9.  Environmental factors affecting antipyrine metabolism in London factory and office workers.

Authors:  H S Fraser; J C Mucklow; C J Bulpitt; C Kahn; G Mould; C T Dollery
Journal:  Br J Clin Pharmacol       Date:  1979-03       Impact factor: 4.335

10.  Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.

Authors:  A R Boobis; M J Brodie; G C Kahn; E L Toverud; I A Blair; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

View more
  1 in total

1.  N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome.

Authors:  W Siegmund; J D Fengler; G Franke; M Zschiesche; O Eike; E Eike; P Meisel; R Wulkow
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.